Clinical Trials Logo

Clinical Trial Summary

The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018_055 in healthy subjects. The study will be conducted in 1 clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose [SAD]) and Part B (multiple ascending dose [MAD]).


Clinical Trial Description

This is a Phase 1, randomized, 2-part (Part A and B), double-blind, placebo controlled single and multiple ascending doses study designed to assess the safety, tolerability, and PK of INS018_055 when administered as oral doses to healthy subjects. Additionally, this study will investigate the impact of food on the PK of INS018_055. Part A (Single Ascending Dose [SAD]): Eight healthy subjects will be assigned to each of up to 5 sequential dose cohorts and will be randomly assigned within each dose cohort to receive INS018_055 or a matched placebo in a ratio of 3:1 (6 active, 2 placebo) on Day 1 for a total of up to approximately 40 subjects. Subjects in Part A will be admitted to the study site on Day -1 and dosed on Day 1 after fasting (nothing to eat or drink, except water) for at least 10 hours. Water is not allowed 1 hour prior to and 1 hour after dosing. Water can be consumed ad libitum at other times. Subjects will remain fasted on Day 1 for 4 hours after dosing. Subjects will be discharged from the study site on Day 4, after the scheduled procedures and review of the Day 4 safety data by the investigator (or designee). Subjects will come back for an end of study (EOS) visit on Day 8 (± 1 day). A sentinel cohort of 2 subjects will be used to mitigate the risk of unexpected adverse events (AEs) not predicted by preclinical pharmacology and toxicology studies for each dosing cohort, starting with Cohort 1 (the initial dose cohort). The sentinel subjects will be dosed in a blinded fashion (1 active, 1 placebo) and monitored for at least 1 day before the remaining 6 subjects in that cohort are dosed. Initiation of dosing of the remaining 6 subjects will depend on an initial safety review by the investigator indicating that administration of the study treatment was safe and well tolerated in the sentinel subjects. Dose escalation will occur only after the real time PK, safety, and tolerability data (including reported AEs, physical examinations, vital signs, electrocardiograms (ECGs), and clinical laboratory results up to 48 hours after dosing) of the preceding dose cohort for at least 6 subjects are assessed and the study treatment is deemed safe and well tolerated by the safety review committee (SRC). As new safety and/or PK data become available, the anticipated dose escalation scheme may change following a review of the data by the SRC. Preliminary PK data from subjects in this study will help guide dose escalation to higher doses. Dose escalation in Cohorts 4 and 5 will only occur after the PK data from at least the first 2 cohorts have been assessed and deemed sufficient to model exposures for Cohorts 4 and 5. Food Effect Assessment (Cohort 4 in Part A only): Subjects in Cohort 4 of Part A will participate in a food effect arm. The actual dose level for food effect cohort is subject to change and will be confirmed by the SRC after review of data from at least the first 2 cohorts of the SAD. Following the standard SAD dosing on Day 1 and at least 3 days of follow up/washout (or 5 times the estimated half-life of INS018_055 based on the observed data, whichever is longer) (Period 1), enrolled subjects will enter Period 2 and be re administered the same dose of INS018_055 or matching placebo (the same treatment that they received on Day 1 of Period 1) after completing a standard high-fat meal. Subjects will fast (nothing to eat and drink, except water) for at least 10 hours overnight and receive a standard high-fat breakfast 30 minutes prior to dosing. The high-fat breakfast will be consumed within approximately 30 minutes. Subjects will remain at the study site on Day 4 of Period 2 until the scheduled procedures and review of the Day 4 safety data by the investigator (or designee) are completed. The washout period of at least 3 days (or 5 times the estimated half life of INS018_055 based on the observed data, whichever is longer) may be extended based on available PK data from previous cohorts. The Day -1 procedures will not be repeated for Period 2. Physical examinations, vital sign measurements, 12-lead ECGs, and clinical laboratory evaluations will be performed at selected time points throughout the study. Subjects will also be closely monitored for AEs throughout the study. Blood samples for PK will be collected up to 72 hours after study treatment administration on Day 1 for all cohorts. For biomarkers (CD4+ and CD8+ T-cells), blood samples will be collected at check-in (Day -1), Day 2, and Day 4 after administration of INS018_055. Fecal occult blood tests will be done with all stools passed at screening, check-in (Day -1), and during the 72 hour observation period. Subjects will be discharged on Day 4. Part B (Multiple Ascending Dose [MAD]): Eight healthy subjects will be assigned to each of up to 5 sequential once daily (QD) or twice daily (BID) dose cohorts and will be randomly assigned within each dose cohort to receive INS018_055 or a matched placebo for 10 days in a ratio of 3:1 (6 active, 2 placebo), for a total of up to approximately 40 subjects. Subjects in Part B will begin dosing, after safety and tolerability data (including reported AEs, physical examination, clinical laboratory results, 12-lead ECGs, and vital signs) from at least the first 3 cohorts (Cohorts 1 to 3) in Part A are assessed and the study treatment is deemed safe and well tolerated by the SRC. Additionally, sufficient PK data from at least the first 3 cohorts of Part A must be obtained to model exposures in Part B. The dosing schedule, either QD or BID, will be decided by the SRC after review of the PK, safety, and tolerability data from the first 3 cohorts of Part A. The initial MAD cohorts will begin dosing with the remaining SAD cohorts. The top dose explored in Part B will not exceed the maximum dose explored in Part A. Subsequent dose escalations in Part B will not occur until the safety (including AEs, physical examination, clinical laboratory results, vital signs, and 12-lead ECGs) and tolerability data up to and including Day 14 of the preceding MAD dose cohort for at least 6 subjects are assessed and the study treatment is deemed safe by the SRC. As new safety or PK data become available, the dose escalation scheme may change. Subjects may not receive a subsequent higher dose and may instead be administered a lower dose or may repeat the same daily dose with a different administration schema, eg, BID instead of QD dosing, to achieve lower maximum observed plasma concentration (Cmax) values, particularly if the safety findings are believed to be linked to the Cmax values. The highest dose in the MAD (either QD or BID) will be dosed in a staggered way if accrued PK data from previous cohorts predict potential exposures above the no observed adverse effect level, with 2 subjects starting dosing at least 7 days before the remaining 6 subjects; initiation of dosing of the remaining 6 subjects will depend on an initial safety review by the investigator indicating that administration of the study treatment was safe and well tolerated in the sentinel subjects. Each subject in Part B will be admitted to the study site on Day -1 and will begin daily dosing on Day 1. Study treatment is to be administered daily at approximately the same time in the morning. For BID dosing, the second dose of study treatment will be administered approximately 12 hours after the morning dose of study treatment. Prior to the morning dosing on Days 1 and 10 for Cohorts 6 to 10, subjects will fast (nothing to eat and drink, except water) for at least 10 hours overnight and remain fasted for 4 hours after study treatment administration. Water is not allowed 1 hour prior to and 1 hour after dosing. Water can be consumed ad libitum at other times. Water is not restricted for the evening doses when study treatment is being dosed BID. On Days 1 and 10, lunch will be provided approximately 4 hours after the morning dose, dinner will be provided approximately 10 hours after the morning dose, and a snack will be provided approximately 13 hours after the morning dose. On Days 2 to 9 for Cohorts 6 to 10, breakfast will be provided approximately 60 minutes after study treatment administration. Standardized meals will be provided to the subjects throughout the study. Lunch will be provided approximately 4 hours after the morning dose, dinner will be provided approximately 10 hours after the morning dose, and a snack will be provided approximately 13 hours after the morning dose. Physical examinations, vital sign measurements, 12-lead ECGs, and clinical laboratory evaluations (including liver function test results) will be performed at selected time points throughout the dosing interval. Subjects will be closely monitored for AEs throughout the study. Blood samples for PK analyses will be collected up to 72 hours after study treatment administration on Day 10. Urine samples for PK analysis will be collected before dosing (Day 1 as a single void collected within 0 to 24 hours) and over the following intervals after dosing: 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours on Day 1 and 0 to 4, 4 to 8, 8 to 12, 12 to 24, and 24 to 48 hours on Day 10 for both QD and BID cohorts. For biomarkers (CD4+ and CD8+ T-cells), blood samples will be collected at selected time points for QD and BID dosing cohorts. Fecal occult blood tests will be done with all stool samples at screening, check-in (Day 1), and throughout Part B on site observation periods, ie, up to Day 14. Subjects will be discharged from the study site on Day 14, after the scheduled procedures and review of the safety data by the investigator (or designee). Subjects will return to the study site on Day 28 (± 3 days) for an EOS visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05154240
Study type Interventional
Source InSilico Medicine Hong Kong Limited
Contact
Status Completed
Phase Phase 1
Start date February 21, 2022
Completion date December 2, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Active, not recruiting NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3
Completed NCT00532233 - SD, IL-13 Production Rate in IPF Phase 2
Completed NCT00540475 - Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry